Related Experiment Video

Updated: Nov 23, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.1K

Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy

Bayan Al-Share1, Nour Hammad2, Maria Diab3

  • 1Department of Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI, USA.

Cancer Metastasis Reviews
|January 5, 2021
PubMed

Insights

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, but targeted therapies show promise. Genomic profiling and germline testing are crucial for identifying patients who may benefit from these advanced treatments.

Area of Science:

  • Oncology
  • Genetics
  • Cancer Research

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) remains a significant challenge with poor patient outcomes.
  • Traditional chemotherapy is the primary treatment, but its efficacy is limited.
  • Recent advancements suggest targeted therapy offers a promising avenue for improving PDAC management.

Purpose of the Study:

  • To highlight the potential of targeted therapy in managing pancreatic cancer.
  • To emphasize the importance of genomic and germline testing in identifying suitable candidates for targeted treatments.
  • To discuss the ongoing research into new markers and agents for PDAC.

Main Methods:

  • Review of recent advancements in PDAC treatment strategies.
  • Emphasis on the role of genomic profiling of tumor tissue.
  • Highlighting the significance of germline testing in patient assessment.

Main Results:

  • Targeted therapy presents a promising approach for a subset of PDAC patients.
  • Genomic and germline testing are essential for identifying actionable targets.
  • Ongoing research continues to uncover new therapeutic markers and agents.

Conclusions:

  • Timely genomic and germline testing are critical for optimizing PDAC patient care.
  • Targeted therapies, while currently for a select group, hold potential for improved outcomes.
  • Continued research is vital for expanding the application and efficacy of targeted agents in PDAC.
Keywords:
CellularMolecular driversPancreatic cancerTargeted therapy

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.8K
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

3.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K